- Home
- PEN vs HALO Comparison
PEN vs HALO Comparison
Compare PEN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- HALO
- Stock Information
- Founded
- PEN 2004
- HALO 1998
- Country
- PEN United States
- HALO United States
- Employees
- PEN N/A
- HALO N/A
- Industry
- PEN Medical/Dental Instruments
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEN Health Care
- HALO Health Care
- Exchange
- PEN Nasdaq
- HALO Nasdaq
- Market Cap
- PEN 9.9B
- HALO 9.0B
- IPO Year
- PEN 2015
- HALO N/A
- Fundamental
- Price
- PEN $256.09
- HALO $68.98
- Analyst Decision
- PEN Strong Buy
- HALO Buy
- Analyst Count
- PEN 16
- HALO 10
- Target Price
- PEN $302.93
- HALO $73.40
- AVG Volume (30 Days)
- PEN 432.3K
- HALO 2.2M
- Earning Date
- PEN 10-29-2025
- HALO 10-30-2025
- Dividend Yield
- PEN N/A
- HALO N/A
- EPS Growth
- PEN 916.05
- HALO 68.93
- EPS
- PEN 3.74
- HALO 4.37
- Revenue
- PEN $1,280,152,000.00
- HALO $1,178,672,000.00
- Revenue This Year
- PEN $15.52
- HALO $32.57
- Revenue Next Year
- PEN $14.20
- HALO $23.25
- P/E Ratio
- PEN $68.49
- HALO $15.80
- Revenue Growth
- PEN 12.92
- HALO 34.97
- 52 Week Low
- PEN $189.94
- HALO $42.01
- 52 Week High
- PEN $310.00
- HALO $79.50
- Technical
- Relative Strength Index (RSI)
- PEN 47.86
- HALO 35.36
- Support Level
- PEN $242.41
- HALO $73.06
- Resistance Level
- PEN $257.56
- HALO $76.30
- Average True Range (ATR)
- PEN 7.03
- HALO 2.25
- MACD
- PEN -1.00
- HALO -1.13
- Stochastic Oscillator
- PEN 62.21
- HALO 8.18
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.